Fulcrum Therapeutics Inc (FULC) is a Healthcare · Biotechnology company listed on NASDAQ. Price $3.76 (-0.27%), Market cap $0.49B, 52-week low–high $5.07 ~ $14.60.
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia. The company also discovers programs for the treatment of diamond-blackfan anemia, Bone Marrow Failure Syndromes, novel fetal hemoglobin inducers, fibrotic disorders. It has licensce agreement with CAMP4 which includes certain small molecule compounds, composition of matter and method of use pate
Financial statements, price targets, institutional (13F) holdings and related news for Fulcrum Therapeutics Inc are updated in real time on BlackAll Trade.
Fulcrum Therapeutics Inc trades at $3.76 (-0.27%). Real-time quotes and charts are available on BlackAll Trade.
Fulcrum Therapeutics Inc has a market cap of about $0.49B.
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical n